Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.65 |
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.50 |
| ▸ | PHGDH | O43175 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589664 | 1.00 | HSP90AA1 (0.65) | HSP90AA1HKDC1PHGDHALDH1A1GAA | |
| SCHEMBL22589793 | 0.88 | HSP90AA1 (0.58) | HSP90AA1HKDC1ALDH1A1MITFHTT | |
| SCHEMBL22589794 | 0.88 | HSP90AA1 (0.58) | HSP90AA1HKDC1ALDH1A1MITFHTT | |
| SCHEMBL17975297 | 0.81 | HSP90AA1 (0.65) | HSP90AA1HKDC1PHGDHALDH1A1MITF | |
| SCHEMBL22589669 | 0.80 | HKDC1 (0.43) | HSP90AA1HKDC1ALDH1A1GAALMNA | |
| SCHEMBL9321800 | 0.79 | HSP90AA1 (1.00) | HSP90AA1HKDC1ALDH1A1MITFHTT | |
| SCHEMBL26087734 | 0.79 | HSP90AA1 (1.00) | HSP90AA1HKDC1ALDH1A1MITFHTT | |
| SCHEMBL17975335 | 0.79 | HSP90AA1 (1.00) | HSP90AA1HKDC1ALDH1A1MITFHTT | |
| SCHEMBL29882936 | 0.79 | HSP90AA1 (1.00) | HSP90AA1HKDC1ALDH1A1MITFHTT | |
| SCHEMBL24512361 | 0.78 | HSP90AA1 (0.51) | HSP90AA1HKDC1ALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344626-B2 | Pharmaceutical compounds and therapeutic methods | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-07-01 | — | — | US | disclosed |
| US-20220185827-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220185827-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-06-16 | — | — | US | disclosed |
| WO-2020219587-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344626-B2 | Pharmaceutical compounds and therapeutic methods | SLC30A5, SLC39A11, SLC30A7 | HSP90AA1 2676/4885HKDC1 644/4885PHGDH 1918/4885 |
| US-20220185827-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | SLC30A5, SLC39A11, SLC30A7 | HSP90AA1 2676/4885HKDC1 644/4885PHGDH 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.